GlassScriptPhysician profile
David Benjamin Holt
NPI 1912533589
$3,531.22
in general payments reported to CMS, 2019-2025
30 companies · $966 in 2025
The $966 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,226 · 2022: $498 · 2023: $400 · 2024: $441 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $649.63 | 2021-2025 | Relistor, Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $398.91 | 2021 | |
| Collegium Pharmaceutical, INC. | $373.05 | 2021-2025 | Belbuca, Xtampza |
| Abbvie INC. | $264.00 | 2021-2024 | |
| Eisai INC. | $220.19 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $211.97 | 2025 | Nuzyra, Xhance |
| Teva Pharmaceuticals USA, INC. | $180.41 | 2024-2025 | Austedo Xr, Austedo Xr |
| Grt US Holding, INC. | $163.07 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $148.99 | 2023-2024 | Ingrezza |
| Pfizer INC. | $135.55 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2025 | Caplyta |
| Averitas Pharma INC. | $77.79 | 2023-2024 | Qutenza |
| Valinor Pharma, LLC | $60.08 | 2025 | Movantik |
| Sunovion Pharmaceuticals INC. | $51.07 | 2021 | |
| Scilex Pharmaceuticals INC. | $49.93 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $48.74 | 2021 | |
| Redhill Biopharma INC. | $43.76 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.75 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $41.63 | 2025 | Rexulti |
| Sun Pharmaceutical Industries INC. | $33.87 | 2021 | |
| Biodelivery Sciences International, INC. | $27.79 | 2021 | |
| Lilly USA, LLC | $26.88 | 2021-2024 | Taltz |
| Axsome Therapeutics, INC. | $24.67 | 2025 | Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.06 | 2022 | |
| Vanda Pharmaceuticals INC. | $22.76 | 2025 | Fanapt, Hetlioz |
| Vertex Pharmaceuticals Incorporated | $21.71 | 2025 | |
| Janssen Biotech, INC. | $17.71 | 2024 | Tremfya |
| Tonix Medicines, INC. | $17.07 | 2025 | Tonmya |
| Urovant Sciences INC | $16.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.